Arbutus Biopharma Corp. (ABUS) NASDAQ
$2.64 (0.08) (-2.94%)
Market Cap: $488.22M
As of 04/22/24 04:00 PM EDT. Market closed.
Arbutus Biopharma Corp. (ABUS)
NASDAQ
$2.64
(0.08) (-2.94%)
Market Cap: $488.22M
As of 04/22/24 04:00 PM EDT. Market closed.
Add to Portfolio
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
William Collier
Full Time Employees
106
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
William Collier
Full Time Employees
106
CEO Compensation (Base)
$556,000
Address
701 Veterans Circle, Pennsylvania, Warminster, 18974.
PRICE CHART FOR ARBUTUS BIOPHARMA CORP
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$2.73
Previous Close
$2.72
Days Range
$2.63 - $2.74
52 week range
$1.69 - $3.29
Volume
740,415
Avg. Volume (30 days)
2,272,604
Market Cap
$488.22M
Dividend Yield
-
P/E
(6.70)
Shares Outstanding
179,492,199
Open
$2.73
Previous Close
$2.72
Days Range
$2.63 - $2.74
52 week range
$1.69 - $3.29
Volume
740,415
Avg. Volume (30 days)
2,272,604
Market Cap
$488.22M
Dividend Yield
-
P/E
(6.70)
Shares Outstanding
179,492,199
FINANCIAL STATEMENTS FOR ARBUTUS BIOPHARMA CORP
LOADING...
INSIDER TRANSACTIONS FOR ARBUTUS BIOPHARMA CORP
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Sims Karen | Chief Medical Officer | Feb 02, 2024 | Sale | $2.31 | 4,358 | 10,078 | 125,542 | Feb 05, 2024, 07:55 PM |
HASTINGS DAVID C | Chief Financial Officer | Feb 02, 2024 | Sale | $2.31 | 9,593 | 22,184 | 181,907 | Feb 05, 2024, 07:54 PM |
Sofia Michael J. | Chief Scientific Officer | Feb 02, 2024 | Sale | $2.31 | 9,982 | 23,083 | 1,485,121 | Feb 05, 2024, 07:54 PM |
McElhaugh Michael J. | Interim President & CEO | Feb 02, 2024 | Sale | $2.31 | 10,164 | 23,504 | 1,504,793 | Feb 05, 2024, 07:54 PM |
Sofia Michael J. | Chief Scientific Officer | Dec 01, 2021 | Sale | $5.09 | 200,000 | 1,018,000 | 1,303,403 | Dec 03, 2021, 04:02 PM |
McElhaugh Michael J. | Chief Business Officer | Feb 09, 2021 | Sale | $5.00 | 20,000 | 100,000 | 1,307,457 | Feb 10, 2021, 05:06 PM |
McElhaugh Michael J. | Chief Business Officer | Dec 14, 2020 | Sale | $5.00 | 40,000 | 200,032 | 1,337,457 | Dec 16, 2020, 04:33 PM |
McElhaugh Michael J. | Chief Business Officer | Jul 23, 2020 | Sale | $5.01 | 20,000 | 100,200 | 1,367,457 | Jul 27, 2020, 05:27 PM |
Murray Mark J. | Director | Nov 28, 2018 | Option Exercise | $1.35 | 25,000 | 33,750 | 341,396 | Nov 30, 2018, 04:55 PM |
Sofia Michael J. | Chief Scientific Officer | Aug 13, 2018 | Sale | $9.51 | 4,250 | 40,436 | 167,162 | Aug 15, 2018, 03:14 PM |
Sofia Michael J. | Chief Scientific Officer | Aug 13, 2018 | Sale | $9.51 | 4,250 | 40,436 | 1,499,153 | Aug 14, 2018, 06:23 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 11, 2018 | Sale | $10.00 | 10,000 | 100,000 | 1,503,403 | Jul 13, 2018, 01:36 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 06, 2018 | Sale | $8.45 | 10,000 | 84,500 | 1,523,403 | Jul 10, 2018, 01:11 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 09, 2018 | Sale | $8.91 | 10,000 | 89,060 | 1,513,403 | Jul 10, 2018, 01:11 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 05, 2018 | Sale | $8.40 | 10,000 | 84,000 | 1,533,403 | Jul 06, 2018, 04:05 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 03, 2018 | Sale | $8.00 | 10,000 | 80,000 | 1,543,403 | Jul 06, 2018, 04:05 PM |
Murray Mark J. | President & CEO | Apr 17, 2018 | Option Exercise | $0.35 | 27,007 | 9,560 | 316,396 | Apr 17, 2018, 08:22 PM |
Sofia Michael J. | Chief Scientific Officer | Oct 03, 2017 | Sale | $8.00 | 10,000 | 80,000 | 1,553,403 | Oct 05, 2017, 06:34 PM |
Sofia Michael J. | Chief Scientific Officer | Aug 15, 2017 | Sale | $3.70 | 30,000 | 111,000 | 191,412 | Aug 17, 2017, 07:41 PM |
Abrams Michael J. | Managing Director | Aug 16, 2016 | Option Exercise | $0.35 | 14,178 | 4,898 | 42,097 | Aug 18, 2016, 06:11 PM |
Murray Mark J. | President & CEO | Jun 16, 2016 | Option Exercise | $2.57 | 5,000 | 12,844 | 289,389 | Jun 20, 2016, 08:33 PM |
Murray Mark J. | President & CEO | Sep 11, 2015 | Option Exercise | $0.44 | 219,428 | 97,514 | 284,389 | Sep 15, 2015, 04:20 PM |
Abrams Michael J. | Managing Director | Sep 11, 2015 | Option Exercise | $0.44 | 17,044 | 7,574 | 27,919 | Sep 15, 2015, 04:18 PM |
HENRIQUES RICHARD C JR | Director | Aug 24, 2015 | Buy | $6.95 | 1,000 | 6,950 | 1,000 | Aug 26, 2015, 01:29 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
Sims Karen | Chief Medical Officer | 02/02/2024 | 10,078 |
HASTINGS DAVID C | Chief Financial Officer | 02/02/2024 | 22,184 |
Sofia Michael J. | Chief Scientific Officer | 02/02/2024 | 23,083 |
McElhaugh Michael J. | Interim President & CEO | 02/02/2024 | 23,504 |
Sofia Michael J. | Chief Scientific Officer | 12/01/2021 | 1,018,000 |
McElhaugh Michael J. | Chief Business Officer | 02/09/2021 | 100,000 |
McElhaugh Michael J. | Chief Business Officer | 12/14/2020 | 200,032 |
McElhaugh Michael J. | Chief Business Officer | 07/23/2020 | 100,200 |
Murray Mark J. | Director | 11/28/2018 | 33,750 |
Sofia Michael J. | Chief Scientific Officer | 08/13/2018 | 40,436 |
Sofia Michael J. | Chief Scientific Officer | 08/13/2018 | 40,436 |
Sofia Michael J. | Chief Scientific Officer | 07/11/2018 | 100,000 |
Sofia Michael J. | Chief Scientific Officer | 07/06/2018 | 84,500 |
Sofia Michael J. | Chief Scientific Officer | 07/09/2018 | 89,060 |
Sofia Michael J. | Chief Scientific Officer | 07/05/2018 | 84,000 |
Sofia Michael J. | Chief Scientific Officer | 07/03/2018 | 80,000 |
Murray Mark J. | President & CEO | 04/17/2018 | 9,560 |
Sofia Michael J. | Chief Scientific Officer | 10/03/2017 | 80,000 |
Sofia Michael J. | Chief Scientific Officer | 08/15/2017 | 111,000 |
Abrams Michael J. | Managing Director | 08/16/2016 | 4,898 |
Murray Mark J. | President & CEO | 06/16/2016 | 12,844 |
Murray Mark J. | President & CEO | 09/11/2015 | 97,514 |
Abrams Michael J. | Managing Director | 09/11/2015 | 7,574 |
HENRIQUES RICHARD C JR | Director | 08/24/2015 | 6,950 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ARBUTUS BIOPHARMA CORP
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 10,390,300 | 0.00066% | 1.13% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 2,817,695 | 0.00074% | 4.47% | Other |
CHANGE IN SHARES OUTSTANDING FOR ARBUTUS BIOPHARMA CORP
STOCK BUYBACKS FOR ARBUTUS BIOPHARMA CORP
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.64%
1Q
06/30/2023
1.52%
2Q
03/31/2023
4.29%
3Q
12/31/2022
8.35%
4Q
09/30/2022
11.65%
5Q
06/30/2022
13.33%
6Q
03/31/2022
13.58%
7Q
12/31/2021
58.68%
8Q
09/30/2021
66.44%
9Q
06/30/2021
74.03%
10Q
03/31/2021
80.43%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ARBUTUS BIOPHARMA CORP
LOADING...